← Eichor
Study identifier: NCT07691125 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase IV Study of rhGH Injection in Adult Short Bowel Syndrome

Condition: Short Bowel Syndrome (SBS) in Adults  ·  Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

PhasePhase 4
Planned participants100
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a multicenter, open-label, single-arm clinical trial. A total of 100 participants with short bowel syndrome (SBS) receiving parenteral nutrition (PN) support are planned to be enrolled. The trial includes a 2-week run-in phase and a 4-week intervention phase, during which participants will receive rhGH injections. A safety follow-up period will then be conducted through Week 52.

This description comes directly from the study's public registry record.

Talk to the study team

Feifei Liu  ·  +86 13156199093  ·  liufeifei@genscigroup.com

Always discuss trial participation with your own doctor first.

Locations (2)

Zhongshan Hospital Affiliated to Xiamen UniversityXiamen, Fujian, ChinaRecruiting
General Hospital of Eastern Theater CommandNanjing, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07691125